+

WO2017011820A3 - Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires - Google Patents

Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires Download PDF

Info

Publication number
WO2017011820A3
WO2017011820A3 PCT/US2016/042680 US2016042680W WO2017011820A3 WO 2017011820 A3 WO2017011820 A3 WO 2017011820A3 US 2016042680 W US2016042680 W US 2016042680W WO 2017011820 A3 WO2017011820 A3 WO 2017011820A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukin
receptor
peptide inhibitors
inflammatory diseases
treat inflammatory
Prior art date
Application number
PCT/US2016/042680
Other languages
English (en)
Other versions
WO2017011820A2 (fr
Inventor
Gregory BOURNE
Xiaoli Cheng
Brian Troy FREDERICK
Jie Zhang
Dinesh V. Patel
David Liu
Ashok Bhandari
Original Assignee
Protagonist Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/fr
Priority to CN201680049562.2A priority Critical patent/CN108348580B/zh
Priority to UAA201801482A priority patent/UA123772C2/uk
Priority to EP16825301.1A priority patent/EP3341011A4/fr
Priority to BR112018000691A priority patent/BR112018000691A2/pt
Priority to CR20180029A priority patent/CR20180029A/es
Priority to KR1020187004612A priority patent/KR102513978B1/ko
Application filed by Protagonist Therapeutics, Inc. filed Critical Protagonist Therapeutics, Inc.
Priority to CA2991984A priority patent/CA2991984A1/fr
Priority to US15/745,371 priority patent/US10787490B2/en
Priority to EA201890325A priority patent/EA035733B9/ru
Priority to MX2018000542A priority patent/MX384213B/es
Priority to AU2016293619A priority patent/AU2016293619B2/en
Priority to JP2018501178A priority patent/JP6858174B2/ja
Publication of WO2017011820A2 publication Critical patent/WO2017011820A2/fr
Publication of WO2017011820A3 publication Critical patent/WO2017011820A3/fr
Priority to PH12018500086A priority patent/PH12018500086A1/en
Priority to DO2018000010A priority patent/DOP2018000010A/es
Priority to IL256827A priority patent/IL256827A/en
Priority to NI201800008A priority patent/NI201800008A/es
Priority to CONC2018/0000349A priority patent/CO2018000349A2/es
Priority to SV2018005614A priority patent/SV2018005614A/es
Priority to ECIEPI20182929A priority patent/ECSP18002929A/es
Priority to HK19100122.0A priority patent/HK1257747A1/zh
Priority to HK19101174.5A priority patent/HK1259149A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouveaux peptides inhibiteurs du récepteur de l'interleukine-23 et des compositions associées et des procédés d'utilisation de ces peptides inhibiteurs pour traiter ou prévenir divers troubles et maladies, notamment les maladies inflammatoires de l'intestin.
PCT/US2016/042680 2015-07-15 2016-07-15 Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires WO2017011820A2 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
JP2018501178A JP6858174B2 (ja) 2015-07-15 2016-07-15 インターロイキン２３受容体のペプチド阻害剤、および炎症性疾患を処置するためのそれらの使用
MX2018000542A MX384213B (es) 2015-07-15 2016-07-15 Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
EP16825301.1A EP3341011A4 (fr) 2015-07-15 2016-07-15 Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
BR112018000691A BR112018000691A2 (pt) 2015-07-15 2016-07-15 inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
CR20180029A CR20180029A (es) 2015-07-15 2016-07-15 Inhibidores peotídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
KR1020187004612A KR102513978B1 (ko) 2015-07-15 2016-07-15 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 그의 용도
UAA201801482A UA123772C2 (uk) 2015-07-15 2016-07-15 Пептидний інгібітор рецептора інтерлейкіну-23 та спосіб лікування запального захворювання кишечнику (ibd)
CA2991984A CA2991984A1 (fr) 2015-07-15 2016-07-15 Peptides inhibiteurs du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
US15/745,371 US10787490B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EA201890325A EA035733B9 (ru) 2015-07-15 2016-07-15 Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
AU2016293619A AU2016293619B2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN201680049562.2A CN108348580B (zh) 2015-07-15 2016-07-15 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
PH12018500086A PH12018500086A1 (en) 2015-07-15 2018-01-09 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
DO2018000010A DOP2018000010A (es) 2015-07-15 2018-01-10 Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
IL256827A IL256827A (en) 2015-07-15 2018-01-10 Peptide inhibitors of the interleukin-23 receptor and their use in the treatment of inflammatory diseases
NI201800008A NI201800008A (es) 2015-07-15 2018-01-11 Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
ECIEPI20182929A ECSP18002929A (es) 2015-07-15 2018-01-15 Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CONC2018/0000349A CO2018000349A2 (es) 2015-07-15 2018-01-15 Inhibidores peptídicos del receptor de interleucina 23
SV2018005614A SV2018005614A (es) 2015-07-15 2018-01-15 Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
HK19100122.0A HK1257747A1 (zh) 2015-07-15 2019-01-04 白細胞介素-23受體的肽抑制劑以及其治療炎症性疾病的用途
HK19101174.5A HK1259149A1 (zh) 2015-07-15 2019-01-23 白細胞介素-23受體的肽抑制劑以及其治療炎症性疾病的用途

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14/800,627 2015-07-15
USPCT/US15/40658 2015-07-15
PCT/US2015/040658 WO2016011208A1 (fr) 2014-07-17 2015-07-15 Peptides inhibiteurs par voie orale du récepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US62/264,820 2015-12-08
US201662281123P 2016-01-20 2016-01-20
US62/281,123 2016-01-20

Publications (2)

Publication Number Publication Date
WO2017011820A2 WO2017011820A2 (fr) 2017-01-19
WO2017011820A3 true WO2017011820A3 (fr) 2017-02-23

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/042680 WO2017011820A2 (fr) 2015-07-15 2016-07-15 Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires

Country Status (23)

Country Link
EP (1) EP3341011A4 (fr)
JP (1) JP6858174B2 (fr)
KR (1) KR102513978B1 (fr)
CN (1) CN108348580B (fr)
AU (1) AU2016293619B2 (fr)
BR (1) BR112018000691A2 (fr)
CA (1) CA2991984A1 (fr)
CL (3) CL2018000128A1 (fr)
CO (1) CO2018000349A2 (fr)
CR (1) CR20180029A (fr)
DO (1) DOP2018000010A (fr)
EA (1) EA035733B9 (fr)
EC (1) ECSP18002929A (fr)
HK (2) HK1257747A1 (fr)
IL (1) IL256827A (fr)
MX (1) MX384213B (fr)
NI (1) NI201800008A (fr)
PE (1) PE20180571A1 (fr)
PH (1) PH12018500086A1 (fr)
SG (1) SG10201912066SA (fr)
SV (1) SV2018005614A (fr)
UA (1) UA123772C2 (fr)
WO (1) WO2017011820A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014145561A2 (fr) 2013-03-15 2014-09-18 Protagonist Therapeutics, Inc. Analogues d'hepcidine et leurs utilisations
WO2014172644A2 (fr) 2013-04-19 2014-10-23 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr
KR102787208B1 (ko) 2014-05-16 2025-03-27 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 티오에테르 펩티드 길항제
RU2736637C9 (ru) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
MX391184B (es) 2014-10-01 2025-03-19 Protagonist Therapeutics Inc ANTAGONISTAS DE MONOMÉRICOS Y DIMÉRICOS PEPTÍDICOS DE a4ß7 NOVEDOSOS.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3009834A1 (fr) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree
CA3017926C (fr) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Procedes de synthese d'antagonistes de peptide .alpha.4.beta.7
WO2018136646A1 (fr) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
CA3073806A1 (fr) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Peptides d'agoniste opioide et leurs utilisations
EP3749345A4 (fr) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. Mimétiques d'hepcidine conjugués
PL3788047T3 (pl) 2018-05-04 2025-04-14 Incyte Corporation Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
WO2019213506A1 (fr) 2018-05-04 2019-11-07 Incyte Corporation Sels d'un inhibiteur de fgfr
US20200040037A1 (en) * 2018-07-12 2020-02-06 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP3819307A1 (fr) 2019-11-07 2021-05-12 CytoKi Pharma ApS Dérivés thérapeutiques de l'interleukine-22
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of an fgfr inhibitor
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022013957A2 (pt) * 2020-01-15 2022-10-11 Janssen Biotech Inc Inibidores peptídicos do receptor de interleucina-23 e uso dos mesmos para tratar doenças inflamatórias
CN115279782A (zh) * 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
PE20240631A1 (es) * 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23
WO2022221170A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AU2022310347A1 (en) * 2021-07-14 2024-02-29 Janssen Biotech, Inc. Bicyclic peptide inhibitors of interleukin-23 receptor
EP4440592A1 (fr) 2021-12-01 2024-10-09 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
WO2023172648A2 (fr) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Substrats fluorogènes pour la détection d'aminopeptidase dans des fluides biologiques
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
AU2023300411A1 (en) 2022-06-30 2025-02-13 Sanofi New peptides as selective il-23 receptor antagonists
WO2024110477A2 (fr) * 2022-11-21 2024-05-30 Janssen Pharmaceutica Nv Synthèse d'un peptide cyclique
WO2024155551A1 (fr) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Inhibiteurs peptidiques polycycliques du récepteur de l'interleukine-23
WO2024155547A2 (fr) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Inhibiteurs peptidiques du récepteur de l'interleukine-23
WO2024163643A1 (fr) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Procédés de préparation d'inhibiteurs peptidiques cristallins du récepteur de l'interleukine-23
WO2024227437A1 (fr) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 Préparation d'un inhibiteur peptidique du récepteur de l'interleukine-23 et son utilisation
EP4471048A1 (fr) 2023-06-01 2024-12-04 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
EP4471049A1 (fr) 2023-06-01 2024-12-04 Zealand Pharma A/S Inhibiteurs peptidiques du récepteur de l'interleukine-23
WO2025051912A1 (fr) 2023-09-08 2025-03-13 Sanofi Nouveaux peptides en tant qu'inhibiteurs sélectifs du récepteur de l'il-23
WO2025051920A1 (fr) 2023-09-08 2025-03-13 Sanofi Nouveaux peptides en tant qu'inhibiteurs sélectifs du récepteur de l'il-23

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CA2707840A1 (fr) 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
US9523073B2 (en) * 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2015054500A2 (fr) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonistes de guanylate cyclase utiles pour la régulation négative de cytokines pro-inflammatoires
RU2736637C9 (ru) * 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166514A1 (en) * 1996-11-12 2003-09-04 Jones Terence R. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
US20130172272A1 (en) * 2011-06-14 2013-07-04 Medical Diagnostic Laboratories Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof

Also Published As

Publication number Publication date
JP6858174B2 (ja) 2021-04-14
CL2018000128A1 (es) 2018-06-15
IL256827A (en) 2018-03-29
SV2018005614A (es) 2018-05-22
PE20180571A1 (es) 2018-04-04
UA123772C2 (uk) 2021-06-02
KR102513978B1 (ko) 2023-03-27
NI201800008A (es) 2018-06-29
KR20180030663A (ko) 2018-03-23
EA201890325A1 (ru) 2018-06-29
EA035733B1 (ru) 2020-07-31
CN108348580B (zh) 2022-05-10
AU2016293619A1 (en) 2018-02-01
EP3341011A4 (fr) 2019-02-20
BR112018000691A2 (pt) 2018-09-18
MX384213B (es) 2025-03-14
AU2016293619B2 (en) 2021-02-25
SG10201912066SA (en) 2020-02-27
ECSP18002929A (es) 2018-03-31
CL2018003322A1 (es) 2019-01-18
CL2021000343A1 (es) 2021-08-06
CA2991984A1 (fr) 2017-01-19
HK1259149A1 (zh) 2019-11-29
WO2017011820A2 (fr) 2017-01-19
EA035733B9 (ru) 2021-01-14
DOP2018000010A (es) 2018-03-30
HK1257747A1 (zh) 2019-10-25
PH12018500086A1 (en) 2018-07-30
JP2018522008A (ja) 2018-08-09
CN108348580A (zh) 2018-07-31
CR20180029A (es) 2018-06-05
MX2018000542A (es) 2018-06-27
CO2018000349A2 (es) 2018-07-10
EP3341011A2 (fr) 2018-07-04

Similar Documents

Publication Publication Date Title
WO2017011820A3 (fr) Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
EP4378536A3 (fr) Inhibiteurs peptidiques oraux du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies intestinales inflammatoires
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2017098328A8 (fr) Composés inhibiteurs thérapeutiques
WO2016130920A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
WO2016011306A3 (fr) Modifications de terminal de polynucléotides
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
WO2015168532A3 (fr) Compositions et procédés de modulation de l'expression de pkk
WO2016100157A3 (fr) Antagonistes octahydropyrrolopyridines 6,5-bicycliques du récepteur d'orexine
WO2016100162A3 (fr) Antagonistes oxazoles 5,5-bicycliques du récepteur d'orexine
WO2016044463A3 (fr) Inhibiteurs de mk2 et leurs utilisations
WO2016098079A3 (fr) Compositions et méthodes associées à des anticorps ciblant bmp6
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
EP3256438A4 (fr) Composés, compositions, et procédés de traitement de maladies inflammatoires, dégénératives, et neurodégénératives
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
WO2015120062A8 (fr) Composés et compositions thérapeutiques
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EP3348273B8 (fr) Compositions à base de protéines et de xyloglucane pour le traitement de troubles intestinaux
WO2018226992A8 (fr) Inhibiteur d'agrégation de tau
EP3223809A4 (fr) Compositions d'acide aminé pour le traitement de symptômes de maladie
EA201791937A1 (ru) Противовоспалительные полипептиды
PH12017500114A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825301

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11201710859R

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2991984

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12018500086

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 256827

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2018-000008 I

Country of ref document: NI

Ref document number: 000053-2018

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2018501178

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/000542

Country of ref document: MX

Ref document number: CR2018-000029

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: NC2018/0000349

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016293619

Country of ref document: AU

Date of ref document: 20160715

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187004612

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201801482

Country of ref document: UA

Ref document number: 2016825301

Country of ref document: EP

Ref document number: 201890325

Country of ref document: EA

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825301

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018000691

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018000691

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180112

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载